When the cancer stem cell fraction surviving AS602801 treatment was analyzed by flow cytometry, the proportion of CD133-positive cells decreased in a dose-dependent manner in all cancer stem cell lines examined (Figure 3A). Here, PROM1 is linked to cancer.